Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiac Biotech SolutionsCBSC EV-to-EBIT is -12.18 as of Jul. 14, 2026. Among 466 Medical Devices & Instruments companies, Cardiac Biotech Solutions ranks worse than 214592.06% on this metric.
The historical rank and industry rank for Cardiac Biotech Solutions's EV-to-EBIT or its related term are showing as below:
CBSC's EV-to-EBIT is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.74 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cardiac Biotech Solutions's Enterprise Value for the quarter that ended in Jun. 2025 was $8.21 Mil.
Cardiac Biotech Solutions's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions EV-to-EBIT Related Terms
Cardiac Biotech Solutions EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's EV-to-EBIT falls into.
Cardiac Biotech Solutions's current Enterprise Value is $5.30 Mil.
Cardiac Biotech Solutions's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a EV-to-EBIT of -12.18 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardiac Biotech Solutions and its competitors. According to the industry distribution chart, Cardiac Biotech Solutions ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Cardiac Biotech Solutions' EV-to-EBIT too high?
Cardiac Biotech Solutions' current EV-to-EBIT is -12.18. Based on the distribution chart, Cardiac Biotech Solutions ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Cardiac Biotech Solutions' EV-to-EBIT compare to LUCY and NXGL?
According to the Medical Devices & Instruments industry distribution chart, Cardiac Biotech Solutions ranks #999999 out of 466 companies for EV-to-EBIT. This places Cardiac Biotech Solutions in the lower half of its industry. The industry median EV-to-EBIT is 18.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.74, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardiac Biotech Solutions and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiac Biotech Solutions's current EV-to-EBIT is -12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current EV-to-EBIT of -12.18. The current EV-to-EBIT is -12.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EV-to-EBIT is -12.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
